Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy

J Infect Dis. 2021 Aug 2;224(3):557-559. doi: 10.1093/infdis/jiab248.

Authors

Rachel Aviv¹, Andrew Weber¹, Tarif Anzum², Matthew Federbush², Diane Horowitz^{3

4}, Effie Singas^{1

4}

Affiliations

¹ Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Northwell Health, Manhasset, New York, USA.
² Department of Medicine, Northwell Health, Manhasset, New York, USA.
³ Division of Rheumatology, Department of Medicine, Northwell Health, Manhasset, New York, USA.
⁴ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hempstead, New York, USA.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antirheumatic Agents* / adverse effects
Arthritis, Rheumatoid* / drug therapy
COVID-19*
Humans
Rituximab / adverse effects
SARS-CoV-2

Substances

Antirheumatic Agents
Rituximab